Navigation Links
Exelixis Announces Full Year and Fourth Quarter 2007 Financial Results
Date:2/14/2008

006. The increase in expenses for the full year and quarter reflects the increased development expenses associated with the continued expansion of our clinical trial activity and the advancement of our compounds through preclinical development.

General and administrative expenses for the year were $44.9 million, compared to $39.1 million in 2006. General and administrative expenses for the quarter were $11.8 million, compared to $11.3 million for the comparable period in 2006. The increase for both the full year and quarter was primarily due to personnel expenses and stock-based compensation expense to support our expanding operations.

Net loss for the year ended December 31, 2007 was $86.4 million, or $0.87 per share, compared to $101.5 million, or $1.17 per share, in 2006. Net loss for the fourth quarter of 2007 was $19.9 million, or $0.19 per share, compared to $25.2 million, or $0.27 per share, for the comparable period in 2006. The decrease in net loss for the full year was primarily due to the $18.8 million gain from the sale of assets recognized in conjunction with our transaction with Agrigenetics, Inc. in September 2007 and an $18.1 million gain on the sale of 80.1% of Artemis Pharmaceuticals to Taconic Farms, Inc. in November 2007. The decrease in net loss for the quarter is primarily due to the $18.1 million gain from the Artemis transaction in November.

Cash and cash equivalents, short-term and long-term marketable securities, investments held by Symphony Evolution, Inc. (a consolidated clinical development financing vehicle) and restricted cash and investments totaled $299.5 million at December 31, 2007, compared to $263.2 million at December 31, 2006.

2007 Highlights

Research & Development

-- Submitted diligence reports on XL647, XL880 and XL784 to

GlaxoSmithKline under our development and commercialization agreement.

-- Initiated a phase 2 trial of XL647 in non-small cell lung cancer


'/>"/>
SOURCE Exelixis, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Exelixis Announces February 14 Webcast of Its Fourth Quarter and Full Year 2007 Financial Results Conference Call
2. Exelixis Announces February 12 Webcast of Presentation at the 10th Annual BIO CEO and Investor Conference
3. Exelixis Announces January 31 Webcast of Presentation at the 2008 Wachovia Healthcare Conference
4. Exelixis Announces Senior Management Promotions
5. Exelixis Announces January 10 Webcast of Presentation at the 26th Annual JPMorgan Healthcare Conference
6. Exelixis Submits XL139 Diligence Report to Bristol-Myers Squibb
7. Reminder: Exelixis Announces December 5 Webcast of Its Third Annual R&D Day
8. Exelixis Announces November 28 Webcast of Presentation at the Lazard Capital Markets Fourth Annual Healthcare Conference
9. Exelixis Announces November 27 Webcast of Presentation at the 19th Annual Piper Jaffray Health Care Conference
10. Exelixis Announces December 5 Webcast of Its Third Annual R&D Day
11. Exelixis Sells 80% Stake in Artemis to Taconic
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/3/2015)... ... July 03, 2015 , ... The ... companies and professional service industries alike-- typically known for its consummate professionalism-- embarks ... a good cause and break from their day jobs. , "Our motto has ...
(Date:7/3/2015)... , July 3, 2015 ... den 22. september 2015 på  http://www.openinnovationinscience.at ... Science", der finder sted i ... nylig undersøgelse af internationale forskere og videnskabsmænd ... de to største udfordringer for sundhedsvidenskaben manglen ...
(Date:7/2/2015)... , ... July 02, 2015 , ... Sleepless nights will ... individual’s quality of sleep, launched its Indiegogo campaign on June 23. Sound sleepers and ... command technology makes it effortless to use, while the integration of the Bluetooth speaker, ...
(Date:7/1/2015)... ... July 01, 2015 , ... The next-generation sequencing (NGS) clinical ... segments, including the molecular diagnostics industry. BCC Research reveals in its new report that ... lower test costs, and a growing need for better diagnostics as part of a ...
Breaking Biology Technology:The Alexander Group Declares Their Independence with a Bit of Levity 2Lancering af verdens første åbne innovationsprogram til uddannelse af forskere 2Lancering af verdens første åbne innovationsprogram til uddannelse af forskere 3Luzi Smart Lamp Recently Launched Indiegogo Campaign 2Luzi Smart Lamp Recently Launched Indiegogo Campaign 3NGS-Based Diagnostics, the ‘Must-Have Platform’, Sends Market Segment CAGRs Soaring According to BCC Research 2NGS-Based Diagnostics, the ‘Must-Have Platform’, Sends Market Segment CAGRs Soaring According to BCC Research 3
... RUTHERFORD, N.J., Nov. 3, 2010 Cambrex Corporation (NYSE: ... 30, 2010. Highlights ... currency, sales decreased 11.5% compared to third quarter 2009.   ... to $11.0 million in the same quarter last year. Debt, ...
... Nov. 3, 2010 Advanced Life Sciences ... a biopharmaceutical company engaged in the discovery, development and commercialization ... and respiratory diseases, today announced that the Company has been ... which was created by Congress as part of the Patient ...
... Board: CVAT, Berlin & Stuttgart: WTC) proudly announces that its ... Exchange under the ticket symbol WTC. CTI,s ... with the listing on the Frankfurt Stock Exchange to help ... visibility and support in the European market.  The listing on ...
Cached Biology Technology:Cambrex Reports Third Quarter 2010 Results 2Cambrex Reports Third Quarter 2010 Results 3Cambrex Reports Third Quarter 2010 Results 4Cambrex Reports Third Quarter 2010 Results 5Cambrex Reports Third Quarter 2010 Results 6Cambrex Reports Third Quarter 2010 Results 7Cambrex Reports Third Quarter 2010 Results 8Cambrex Reports Third Quarter 2010 Results 9IRS Awards Cash Grant to Advanced Life Sciences Under the Qualifying Therapeutic Discovery Project 2IRS Awards Cash Grant to Advanced Life Sciences Under the Qualifying Therapeutic Discovery Project 3Listing on Frankfurt Stock Exchange for CTI (http://ctinanotech.com) 2Listing on Frankfurt Stock Exchange for CTI (http://ctinanotech.com) 3
(Date:6/25/2015)... , June 25, 2015 ... Market by Type (Swipe & Area), Technology, Material (Optical ... Healthcare, Commercial Security & Others) & Geography - ... marketsandmarkets, the said market is expected to reach ... 17.1%. Browse 76 market Tables ...
(Date:6/25/2015)... -- TAKE Solutions Ltd., a global business technology solutions provider, ... and Trademark Office (USPTO) for its "Method for Optimizing ... Accelerators to reduce the time taken to standardize trial ... the accelerators), thus reducing time to market. ... heart of the patented Clinical Data Standardization Process are ...
(Date:6/24/2015)... , June 24, 2015 This report provides ... the next six years. It contains an analysis of ... along with their impact from the short, medium, and ... discusses the industry, market, and technology trends that currently, ... need of concerned authorities to efficiently manage the increasing ...
Breaking Biology News(10 mins):Fingerprint Sensors Market Worth $14,500.07 Million by 2020 2Fingerprint Sensors Market Worth $14,500.07 Million by 2020 3Fingerprint Sensors Market Worth $14,500.07 Million by 2020 4TAKE Solutions Awarded Patent By USPTO 2Automatic Identification System Market by Class, by Platform, by Application and by Geography - Global Forecasts & Analysis to 2014 - 2020 2
... 2011, a team of Chinese and Swedish researchers rediscovered the ... , in the Qinling mountains, Shaanxi province, north central China. ... more in Changqing National Nature Reserves which almost equals ... its discovery in the late 19th century. Nearly all of ...
... a protein that is associated with the spread of cancer ... in chemistry one of this year,s Kaye Innovation Awards at ... a student of Prof. Chaim Gilon and Prof. Alexander Levitzki ... Protein Kinase B (PKB, also called Akt). Since the activation ...
... Inc. (Ticker: MDBX) ( www.medboxinc.com ) today announced their ... Prescription Vending Machines, Inc. (PVM). PVM,s ... appointees by stating, "I am thrilled to have such ... Doctorates and MBAs. We are entering a period of ...
Cached Biology News:Sensational bird finding in China 2Sensational bird finding in China 3Medbox, Inc. Announces New Board of Directors After Acquisition of Prescription Vending Machines, Inc. 2
This free-standing work station safely ventilates fumes upwards, away from the work surface. Optional Exhaust Purification System features bonded charcoal filters that remove organic chemical vapors ...
... Analysis Note: Protein determined by ... 3.2 M (NH 4 ) ... 7.0 Preparation Note: Affinity purified ... suspension • Additives: MgCl 2 ...
... miRNA Bioarray Essentials Kit provides all the necessary ... of the mir Vana miRNA Bioarrays when ... using Ambions mir Vana miRNA Labeling Kit. ... (Bioarray ID BA10001) that should be spiked into ...
... IT siRNA Tracker Intracellular Localization Kit ... straight forward approach to directly label ... in an efficient yet non-destructive manner, ... localization and functional inhibition of target ...
Biology Products: